Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value
$0.91−0.08 (-7.64%)
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Lineage Cell Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Lineage Cell Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was 16.2%. For fiscal 2025 it was -436.5%, against -195.9% the year before. The highest annual figure on record is 566.8% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -436.5% | −240.6 |
| FY2024 | Dec 31, 2024 | -195.9% | +44.3 |
| FY2023 | Dec 31, 2023 | -240.2% | −61.5 |
| FY2022 | Dec 31, 2022 | -178.7% | +812.3 |
| FY2021 | Dec 31, 2021 | -991.0% | +139.8 |
| FY2020 | Dec 31, 2020 | -1130.8% | −797.7 |
| FY2019 | Dec 31, 2019 | -333.1% | +588.9 |
| FY2018 | Dec 31, 2018 | -922.0% | −344.3 |
| FY2017 | Dec 31, 2017 | -577.7% | −1144.5 |
| FY2016 | Dec 31, 2016 | 566.8% | +1234.7 |
| FY2015 | Dec 31, 2015 | -667.9% | +26.5 |
| FY2014 | Dec 31, 2014 | -694.4% | +295.3 |
| FY2013 | Dec 31, 2013 | -989.7% | −442.5 |
| FY2012 | Dec 31, 2012 | -547.2% | −174.8 |
| FY2011 | Dec 31, 2011 | -372.5% | −70.8 |
| FY2010 | Dec 31, 2010 | -301.6% | −34.4 |
| FY2009 | Dec 31, 2009 | -267.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 295.1% | +1104.2 |
| Q2 FY2026 | Jun 30, 2026 | 138.6% | +1240.4 |
| Q1 FY2026 | Mar 31, 2026 | -279.0% | −3.4 |
| Q4 FY2025 | Dec 31, 2025 | 12.9% | +127.0 |
| Q3 FY2025 | Sep 30, 2025 | -809.0% | −728.8 |
| Q2 FY2025 | Jun 30, 2025 | -1101.8% | −692.7 |
| Q1 FY2025 | Mar 31, 2025 | -275.6% | +177.5 |
| Q4 FY2024 | Dec 31, 2024 | -114.1% | +114.6 |
| Q3 FY2024 | Sep 30, 2024 | -80.3% | +490.3 |
| Q2 FY2024 | Jun 30, 2024 | -409.1% | −247.0 |
| Q1 FY2024 | Mar 31, 2024 | -453.0% | −269.8 |
| Q4 FY2023 | Dec 31, 2023 | -228.7% | +103.1 |
| Q3 FY2023 | Sep 30, 2023 | -570.6% | −368.2 |
| Q2 FY2023 | Jun 30, 2023 | -162.1% | −13.6 |
| Q1 FY2023 | Mar 31, 2023 | -183.2% | −47.9 |
| Q4 FY2022 | Dec 31, 2022 | -331.8% | +2150.4 |
| Q3 FY2022 | Sep 30, 2022 | -202.4% | +142.2 |
| Q2 FY2022 | Jun 30, 2022 | -148.5% | +786.6 |
| Q1 FY2022 | Mar 31, 2022 | -135.3% | +226.8 |
| Q4 FY2021 | Dec 31, 2021 | -2482.2% | −3054.6 |
| Q3 FY2021 | Sep 30, 2021 | -344.6% | +1014.4 |
| Q2 FY2021 | Jun 30, 2021 | -935.2% | +754.5 |
| Q1 FY2021 | Mar 31, 2021 | -362.1% | +1271.9 |
| Q4 FY2020 | Dec 31, 2020 | 572.4% | +933.6 |
| Q3 FY2020 | Sep 30, 2020 | -1359.0% | +1551.9 |
| Q2 FY2020 | Jun 30, 2020 | -1689.6% | +2165.6 |
| Q1 FY2020 | Mar 31, 2020 | -1634.0% | −5870.0 |
| Q4 FY2019 | Dec 31, 2019 | -361.2% | +5569.2 |
| Q3 FY2019 | Sep 30, 2019 | -2910.9% | −9705.7 |
| Q2 FY2019 | Jun 30, 2019 | -3855.2% | −3689.7 |
| Q1 FY2019 | Mar 31, 2019 | 4236.0% | +13301.3 |
| Q4 FY2018 | Dec 31, 2018 | -5930.3% | +1681.7 |
| Q3 FY2018 | Sep 30, 2018 | 6794.8% | +5919.4 |
| Q2 FY2018 | Jun 30, 2018 | -165.5% | +2933.2 |
| Q1 FY2018 | Mar 31, 2018 | -9065.3% | −23866.5 |
| Q4 FY2017 | Dec 31, 2017 | -7612.1% | −7163.7 |
| Q3 FY2017 | Sep 30, 2017 | 875.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -3098.7% | – |
| Q1 FY2017 | Mar 31, 2017 | 14801.2% | – |
| Q4 FY2016 | Dec 31, 2016 | -448.3% | – |
See a number that looks wrong?